United Therapeutics won a ruling that Liquidia’s drug infringes its patent, which may protect demand for its own treatments. The court has not yet ordered a label change, so that benefit is not settled.
The ruling may help protect demand for United Therapeutics’ inhaled treatments by limiting a rival’s use for a lung condition. The company is seeking a further court order. The FDA has not withdrawn approval, so that possible benefit is not settled.
Liquidia lost a key patent ruling, and the court rejected its claim that the patent was invalid. United Therapeutics is seeking to remove the lung condition from Liquidia’s drug label, but that change has not been ordered.
Follow United Therapeutics Corp. (UTHR) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for UTHR